People: Agilent Technologies Inc (A.N)

A.N on New York Stock Exchange

20 Sep 2019
Change (% chg)

$-0.10 (-0.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Scangos, George 

Dr. George A. Scangos, Ph.D., is Independent Director of the Company. Dr. Scangos has served as Chief Executive Officer and a director of Vir Biotechnology, Inc. since January 2017. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and a director of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development from 2006 until 2010. He is also a member of the National Board of Visitors of the University of California, Davis School of Medicine and is currently an Adjunct Professor of Biology at Johns Hopkins University.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 194,044
Long-Term Incentive Plans, USD --
All Other, USD 100,000
Fiscal Year Total, USD 294,044

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --